scholarly journals The influence of socioeconomic status and ethnicity on adjuvant systemic treatment guideline adherence for early-stage breast cancer in the Netherlands

2017 ◽  
Vol 28 (8) ◽  
pp. 1970-1978 ◽  
Author(s):  
A. Kuijer ◽  
J. Verloop ◽  
O. Visser ◽  
G. Sonke ◽  
A. Jager ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Socioeconomic Status ◽  
The Netherlands ◽  
Guideline Adherence ◽  
Systemic Treatment ◽  
Early Stage ◽  
Treatment Guideline ◽  
Early Stage Breast Cancer ◽  
Adjuvant Systemic Treatment

Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990–2006 in the southeastern Netherlands

2008 ◽  
Vol 44 (13) ◽  
pp. 1846-1854 ◽  
Author(s):  
Myrthe P.P. Sukel ◽  
Lonneke V. van de Poll-Franse ◽  
Grard A.P. Nieuwenhuijzen ◽  
Gerard Vreugdenhil ◽  
Ron M.C. Herings ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systemic Treatment ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Adjuvant Systemic Treatment

Strong age dependent increase in the use of adjuvant systemic treatment for early stage breast cancer in the period 1990–2006: a population based analysis

2008 ◽  
Vol 6 (7) ◽  
pp. 123
Author(s):  
M.P.P. Sukel ◽  
L.V. van de Poll-Franse ◽  
G.A.R. Nieuwenhuijzen ◽  
A. Vreugdenhil ◽  
R.M.C. Herings ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systemic Treatment ◽  
Early Stage ◽  
Population Based ◽  
Early Stage Breast Cancer ◽  
Adjuvant Systemic Treatment ◽  
Age Dependent

Improving informed breast cancer systemic treatment decision-making.

2018 ◽  
Vol 36 (30_suppl) ◽  
pp. 225-225
Author(s):  
Sarah T. Hawley ◽  
Larry An ◽  
Yun Li ◽  
Reshma Jagsi ◽  
Steven J. Katz
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Systemic Treatment ◽  
Early Stage ◽  
Controlled Trial ◽  
Treatment Decision ◽  
Early Stage Breast Cancer ◽  
Decision Quality ◽  
Decision Tool ◽  
Treatment Decision Making

225 Background: Decision making for adjuvant chemotherapy is increasingly complicated for women with a new diagnosis of early stage breast cancer. Few decision tools are designed to help support informed systemic treatment decision-making, by improving knowledge and decision quality. Methods: We conducted a randomized controlled trial (RCT) of a tailored, comprehensive (locoregional and systemic treatment) and interactive decision tool (iCanDecide), compared with static online information. 537 newly diagnosed, early stage breast cancer patients were enrolled from 22 surgical practices. Participants were surveyed 5 weeks (N = 496; RR 92%) and those eligible for systemic treatment (N = 358) again at 9 months (N = 307; RR 88%). The main outcome for this analysis was knowledge about systemic treatment using 4 true/false items, categorized into high (3- 4 correct) vs. low (0-2 correct). We also assessed subjective decision quality (SDQ) for chemotherapy on a 5-point scale and dichotomized into high (4-5) vs. low (1-3) We evaluated the distribution of participants in each arm, and assessed the association between the study arm and the outcomes using bivariate and multivariable approaches. Results: Of the 358 respondents, 201 did not receive or intend to have chemotherapy. Significantly more intervention than control patients had high knowledge about systemic treatment (52.9% vs. 39.9%, p = 0.012). Overall SDQ for chemotherapy was slightly higher in intervention than control subjects (mean 4.8 vs. 4.6, p = 0.08). However, among women who did not receive chemotherapy, significantly more intervention subjects reported high SDQ than controls (87.1% vs. 75.2%, p = 0.06). Values significantly related to chemotherapy use included avoiding side effects, continuing to work, and being most extensive possible. Conclusions: We found that the interactive decision tool contributed significantly to higher knowledge about systemic treatment among eligible patients. We further found the tool shows promise for improving subjective decision quality, particularly in patients who choose not to have chemotherapy. Further work to integrate tools into the oncology clinical setting is needed. Clinical trial information: NCT01840163.

Socioeconomic Status and Inflammation in Women with Early-stage Breast Cancer: Mediation by Body Mass Index

2021 ◽  
Author(s):  
Yrvane K. Pageot ◽  
Annette L. Stanton ◽  
Patricia A. Ganz ◽  
Michael R. Irwin ◽  
Steve W. Cole ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Socioeconomic Status ◽  
Body Mass ◽  
Early Stage ◽  
Early Stage Breast Cancer

Differential frequency of breast cancer molecular profiling by socioeconomic status in San Diego, California.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e21061-e21061
Author(s):  
Gregory Sumpao Vosganian ◽  
Joshua Daniel Rosenberg ◽  
Radha Verman ◽  
Jill Waalen ◽  
James R. Mason
Keyword(s):  
Breast Cancer ◽  
Socioeconomic Status ◽  
Cancer Patients ◽  
San Diego ◽  
Early Stage ◽  
Molecular Profiling ◽  
Early Stage Breast Cancer ◽  
Low Ses ◽  
Median Income ◽  
Breast Cancer Patients

e21061 Background: Previous reports demonstrate inferior outcomes for cancer patients of low socioeconomic status (SES). The development of breast tumor molecular profiling has optimized anticancer therapy but its effect on outcome for those with barriers to care is unknown. Methods: Breast cancer patients appropriate for OncotypeDX testing (Genomic Health, Inc) were identified from The Scripps Health Tumor Registry. High SES was defined as patients residing in zip codes with a median household income in the top quartile for the county according to the San Diego Association of Governments. Low SES was defined as patients residing in zip codes with median income in the bottom quartile or with Medical as primary insurance. The frequency of OncotypeDX testing, result, therapy prescribed, relapse and cancer specific death rates are reported. Statistical analysis was performed by unpaired t-test; p values≤0.05 were considered significant. Results: 2,192 early-stage breast cancer patients were identified; 167 met criteria. Patients were younger (p<0.0001) and a lower rate of OncotypeDX testing was noted in the low SES group (p=0.028); no difference in stage was observed. All patients were prescribed anti hormone therapy but the low SES group received chemotherapy more frequently (p=0.0075). No difference in relapse rate and no deaths attributable to cancer were noted. Conclusions: We observed a lower rate of OncotypeDX use in the low SES cohort. While the cause is unclear, the higher rate of chemotherapy use in this group may represent overtreatment. Determining a survival impact attributable to this difference requires longer follow-up. Our data demonstrate the need for prospective analysis of tumor profiling use in low SES individuals to ensure early stage breast cancer patients receive optimal therapy. [Table: see text]

Patient Perception of Choice in Decision-Making for Early Stage Breast Cancer: Does Race and Socioeconomic Status Matter?

2011 ◽  
Vol 17 (5) ◽  
pp. 542-544 ◽  
Author(s):  
Shubha Dhage ◽  
Amber A. Guth ◽  
Kezhen Fei ◽  
Jessica Weidman ◽  
Nina A. Bickell
Keyword(s):  
Breast Cancer ◽  
Decision Making ◽  
Socioeconomic Status ◽  
Early Stage ◽  
Patient Perception ◽  
Early Stage Breast Cancer

Preferences of Healthy Inner City Women and the Surgical Treatment of Early Stage Breast Cancer

2007 ◽  
Vol 73 (3) ◽  
pp. 215-221 ◽  
Author(s):  
Victor Fontana ◽  
Tania Castro ◽  
Alain Polynice
Keyword(s):  
Breast Cancer ◽  
Socioeconomic Status ◽  
Radiation Therapy ◽  
Surgical Treatment ◽  
Inner City ◽  
Early Stage ◽  
Breast Conservation ◽  
Breast Conservation Therapy ◽  
Education Level ◽  
Early Stage Breast Cancer

Numerous studies have shown that women of a lower education level and socioeconomic status use less breast-conserving surgery than women of a higher education level and socioeconomic status. Surveys of healthy women and the surgical treatment of early stage breast cancer have been performed. However, no survey has focused exclusively on inner city women. The objective of this study was to determine the awareness, preferences, and concerns of inner-city, multiethnic women and the surgical treatment of stage I and II breast cancer, and to identify if a distinct treatment preference for mastectomy or lumpectomy exists in such a population. The study consisted of a prospective survey of volunteers, age 18 years and older, in the nononcologic clinics of St. Barnabas Hospital in the Bronx, New York. We consecutively surveyed 200 women between the ages of 18 and 75 using a 12-item form from January 2004 to May 2004. Of 200 surveys, 21 were excluded as incomplete and two women surveyed who gave a prior history of breast cancer were excluded from study, leaving 177 total surveys for analysis. Women were presented with a hypothetical diagnosis of early stage breast cancer curable by mastectomy or lumpectomy and radiation therapy. Women were asked about their surgery preferences, who they would seek advice from, if they would let their physician decide treatment, and their concerns if faced with a diagnosis of breast cancer. One hundred seventy-seven completed surveys were obtained; 124 (70%) women chose lumpectomy and radiation, 48 (27%) chose mastectomy, and 5 (3%) chose no treatment. Women who were educated below the collegiate level were more likely to prefer breast conservation therapy compared with those with a college education and above (adjusted OR 1.8, 95% CI 1.0, 3.6). Overall, most women surveyed (62%) were concerned with cancer recurrence followed by the side effects of radiation therapy (19%). Most women surveyed (63%) would make their physician principal advisor, whereas some (23%) would make their significant other the principal advisor. More women who chose mastectomy would make their physician their principal advisor (80%) versus those who chose lumpectomy (65%). More than 80 per cent of the women surveyed would have their physician decide their treatment. The women in the present study exhibited a distinct preference for breast conservation therapy over mastectomy.

Sign in / Sign up

Export Citation Format

Share Document